CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 195 filers reported holding CLOVIS ONCOLOGY INC in Q3 2018. The put-call ratio across all filers is 0.31 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $246,000 | -89.5% | 5,400 | -87.8% | 0.00% | -90.0% |
| Q1 2018 | $2,340,000 | -37.2% | 44,325 | -19.1% | 0.03% | -28.6% |
| Q4 2017 | $3,725,000 | -45.6% | 54,780 | -34.1% | 0.04% | -46.8% |
| Q3 2017 | $6,850,000 | +28.1% | 83,135 | +45.5% | 0.08% | +23.4% |
| Q2 2017 | $5,349,000 | +223.8% | 57,125 | +120.1% | 0.06% | +220.0% |
| Q1 2017 | $1,652,000 | +170.8% | 25,950 | +89.1% | 0.02% | +150.0% |
| Q4 2016 | $610,000 | -60.2% | 13,725 | -67.7% | 0.01% | -55.6% |
| Q3 2016 | $1,532,000 | +571.9% | 42,500 | +553.8% | 0.02% | +500.0% |
| Q4 2015 | $228,000 | -93.8% | 6,500 | -83.6% | 0.00% | -93.9% |
| Q3 2015 | $3,649,000 | +7.3% | 39,680 | +2.5% | 0.05% | +22.5% |
| Q2 2015 | $3,401,000 | +1854.6% | 38,705 | +821.5% | 0.04% | +1900.0% |
| Q2 2014 | $174,000 | -63.6% | 4,200 | -39.1% | 0.00% | -66.7% |
| Q1 2014 | $478,000 | +93.5% | 6,900 | +68.3% | 0.01% | +100.0% |
| Q4 2013 | $247,000 | – | 4,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 814,833 | $60,485,054,000 | 53.20% |
| Palo Alto Investors LP | 2,121,857 | $157,505,000 | 7.79% |
| NEA Management Company, LLC | 2,279,781 | $169,228,000 | 7.65% |
| EcoR1 Capital, LLC | 243,048 | $18,041,000 | 6.01% |
| Redmile Group, LLC | 900,879 | $66,872,000 | 6.00% |
| Opaleye Management Inc. | 140,000 | $10,392,000 | 4.82% |
| PFM Health Sciences, LP | 2,266,756 | $168,261,000 | 4.64% |
| Partner Investment Management, L.P. | 40,798 | $3,028,000 | 4.56% |
| CLIFTON PARK CAPITAL MANAGEMENT, LLC | 826,919 | $61,383,000 | 3.74% |
| Opus Point Partners Management, LLC | 55,988 | $4,156,000 | 3.48% |